A molecular map of the living human brain from quantitative MRI

A molecular map of the living human brain from quantitative MRI | Research Square Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Help Center Sign In Submit a Preprint Cite Share Download PDF Article A molecular map of the living human brain from quantitative MRI Mina Ryten, Melissa Grant-Peters, George Thomas, Daan van Kruining, and 21 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8766017/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted You are reading this latest preprint version Abstract Profiling dynamic molecular processes in neurodegeneration in vivo remains a major clinical challenge. Limited brain tissue accessibility especially limits the development and effective deployment of emerging disease modifying therapies, highlighting the need for non-invasive methods for profiling molecular disease processes. We introduce a non-invasive imaging framework that integrates ultra-high-resolution 7T quantitative MRI (qMRI) with spatially-resolved transcriptomics (SRT) to infer cell-type and pathway-specific molecular features within the cortical grey matter. We demonstrate that our method predicts from qMRI data disease-associated changes to cell type proportions and molecular pathways within the grey matter cortex which are corroborated by orthogonal datasets, including bulk RNA sequencing, single nucleus RNA sequencing and high-performance liquid chromatography. This proof-of-concept establishes the integration of qMRI and SRT as a scalable, non-invasive platform for molecular profiling in neurodegeneration, with significant potential for precision therapeutic monitoring, drug development and clinical trials. Biological sciences/Neuroscience/Cellular neuroscience Health sciences/Neurology/Neurological disorders/Neurodegenerative diseases/Parkinson's disease Full Text Additional Declarations Yes there is potential Competing Interest. RW has received speaking and writing honoraria respectively from GE Healthcare and Britannia, and consultancy fees from Therakind, and is local PI for an EIP neflamapimod trial. Cite Share Download PDF Status: Under Review Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information

Related documents

• Imaging the structural connectome with hybrid MRI-microscopy tractography#1157939
• Mass Spectrometry-Based Spatial Imaging of the Cochlea.#165713
• Dataset for: Functional ultrasound imaging through a human cranial window for mesoscopic mapping of motor effector encoding within the sensorimotor cortex#809976
• Positron Emission Tomography of Amyloid in Alzheimer's Disease#847065
• Neuro-Symbolic Artificial Intelligence: The State of the Art#489552